Lv1
80 积分 2026-07-11 加入
Applicability of Non-Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study
8小时前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1个月前
已完结
186 EXPANDING GLP-1 THERAPY TO LIVER DISEASE: POPULATION-BASED ESTIMATES OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ELIGIBILITY IN THE FRAMINGHAM HEART STUDY
2个月前
已完结
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
2个月前
已完结
皖公网安备34019202002308
